FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “Imagin Medical Reports Physician Feedback On i/Blue(TM) Imaging System For Bladder Cancer Visualization”
Imagin Medical (CSE: IME) (OTCQB: IMEXF) (FRA: DPD2) today reported on-going market research feedback on the i/Blue™ Imaging System which enables simultaneous viewing of white and blue light images during bladder cancer resection.
Imagin Medical is a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures. The Company believes its first product, the i/Blue™ Imaging System, with its proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting cancer for removal, helping to reduce recurrence rates. The Company’s initial focus is bladder cancer. Learn more at www.imaginmedical.com.
Among the many segments within the medical devices industry, one of the most vibrant is that of medical imaging technology. In this market, various technologies such as x-ray scan, MRI, CT-scan and others are used to diagnose diseases and help doctors & physicians decide on the course of treatment. Similar to the medical devices industry, imaging technology growth is heavily dependent on technological advancements, the growing investments made by governments of emerging countries and on the increase of the geriatric population. A recent example of how technology helps transform the sector is the integration of Artificial Intelligence (AI). The use of AI technology in healthcare and medical imaging in particular has changed the way the diagnostic procedure is carried out. The AI assists doctors in both the image capturing process and the diagnoses of these images for the conclusion and personalized treatment of every individual patient. According to a report by Zion Market Research, x-ray devices contributed almost 27.5% of the total revenue generated by the medical imaging market in 2018. However, it is the nuclear imaging equipment segment that is expected to show the fastest growth in the years ahead, due to the on-going developments witnessed in new radiotracers and the rising prevalence of cancer and cardiovascular diseases. Additionally, the global medical imaging market is expected to generate around USD 48.6 Billion by 2025 and at a CAGR of around 5.2% between 2019 and 2025.
In a recent demonstration on how AI can assist in improving medical imaging technology, China rolled out AI based systems that can process hundreds of computed tomography (CT) images in seconds to speed up diagnosis of the coronavirus (COVID-19). Innovation occurs in more traditional imaging methods as well. For instance, earlier in February, a study published in the journal Science Advances describes a new method to detect cancer in its early stages using a targeted MRI contrast agent that binds to proteins. According to the study, with current tests like biopsies, cancer in the liver is often detected in advanced stages, which can limit treatment options and lower overall survival rates. The new MRI method of could potentially have wide-ranging impacts, including more effective diagnosis and precision treatment, as well as less risk to patients. Georgia State University Regents’ Professor Jenny Yang explained that “this is a game changer. It has the possibility to have many more applications, really for any type of cancer… We are already applying it to 10 different types of cancer in the lab… Diagnostic testing using this contrast agent can not only identify the presence of disease but differentiate the stages of disease with high sensitivity and accuracy.”
For more information, please visit: Imagin Medical Inc.
For more corporate news on Imagin Medical Inc., check out the Buzz on the Street
About Buzz on the Street: One of FinancialBuzz.com’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.